Evidence map›Paper›PMID 36436177›Full record

ArticleClinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico2023

Management of high-risk and post-operative non-metastatic prostate cancer in Catalonia: an expert Delphi consensus.

Marta Bonet, David González, José-Enrique Baquedano, Elena García, Manuel Altabas, Francesc Casas, Nicolás Feltes, Ferran Ferrer, Palmira Foro, Rafael Fuentes and 12 more

Abstract readConsensus Statement
PubMed Publisher
In one paragraph

Article in Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 39% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors at 9 institutions in 1 country.

Marta BonetRadiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain. Mabonet.lleida.ics@gencat.cat.ORCID http://orcid.org/0000-0002-6417-0514
David GonzálezRadiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
José-Enrique BaquedanoRadiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Elena GarcíaRadiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Manuel AltabasRadiation Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.
Francesc CasasRadiation Oncology, Hospital Clínic, ICMHO (Institut Clínic de Malalties Hematològiques i Oncològiques), Barcelona, Spain.
Nicolás FeltesRadiation Oncology, Consorci Sanitari de Terrassa, Hospital de Terrassa, Terrassa, Spain.
Ferran FerrerRadiation Oncology, Institut Català d'Oncologia, Hospital Duran i Reynals, Hospitalet de Llobregat, Barcelona, Spain.
Palmira ForoRadiation Oncology, Parc de Salut Mar, Barcelona, Spain.
Rafael FuentesRadiation Oncology, Institut Català d'Oncologia, Hospital Josep Trueta, Barcelona, Spain.
Manuel GaldeanoRadiation Oncology, Consorci Sanitari de Terrassa, Fundació Althaia, Manresa, Spain.
David GomezRadiation Oncology, Hospital Sant Joan de Reus, Reus, Tarragona, Spain.
Ivan HenriquezRadiation Oncology, Hospital Sant Joan de Reus, Reus, Tarragona, Spain.
Josep JovéRadiation Oncology, Institut Català d'Oncologia, Hospital Can Ruti, Badalona, Spain.
Joan LozanoRadiation Oncology, Consorci Sanitari de Terrassa, Hospital de Terrassa, Terrassa, Spain.
Xavier MaldonadoRadiation Oncology, Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus, Barcelona, Spain.ORCID http://orcid.org/0000-0003-2045-4723
Joel MasesRadiation Oncology, Hospital Clínic, ICMHO (Institut Clínic de Malalties Hematològiques i Oncològiques), Barcelona, Spain.
Ismael MembriveRadiation Oncology, Parc de Salut Mar, Barcelona, Spain.
Saturio ParedesRadiation Oncology, Consorci Sanitari de Terrassa, Fundació Althaia, Manresa, Spain.
Àlvar RosellóRadiation Oncology, Institut Català d'Oncologia, Hospital Josep Trueta, Barcelona, Spain.
Gemma SanchoRadiation Oncology, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain.
Moisés MiraRadiation Oncology, Hospital Universitari Arnau de Vilanova, Lleida, Spain.
Hospital Universitari Arnau de Vilanova · ESInstitut Català d'Oncologia · ESAlthaia · ESConsorci Sanitari de Terrassa · ESHospital Clínic de Barcelona · ESHospital Universitari Sant Joan de Reus · ESParc de Salut · ESVall d'Hebron Hospital Universitari · ESHospital de Sant Pau · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo reach a consensus on recommendations for the management of high-risk and post-operative non-metastatic prostate cancer by a group of Radiation Oncologists in Catalonia dedicated to prostate cancer.

methodsA modified Delphi approach was employed to reach consensus on controversial topics in Radiation Oncology on high-risk non-metastatic (eight questions) and post-operative (eight questions) prostate cancer. An agreement of at least 75% was considered as consensus. The survey was electronically sent 6 weeks before an expert meeting where topics were reviewed and discussed. A second-round survey for the controversial questions only was sent and answered by participants after the meeting.

resultsAfter the first round of the survey, 19 experienced Radiation Oncologists attended the meeting and 74% fulfilled the second-round online questionnaire. An agreement of 9 of the 16 questions was accounted for the first round. After the meeting, an additional agreement was reached in 3 questions leading to a final consensus on 12 of the 16 questions. There are still controversial topics like the use of PET for staging of high-risk and post-operative non-metastatic prostate cancer and the optimal dose to the prostate bed in the salvage setting.

conclusionThis consensus contributes to establish recommendations and a framework to help in prostate cancer radiation therapy and pharmacological management in daily clinical practice of high-risk and post-operative non-metastatic prostate cancer.

Indexed as

Prostatic NeoplasmsDelphi TechniqueHumansMaleSpainSurveys and QuestionnairesDelphi consensusHigh-riskNon-metastaticProstate cancer

Identifiers

PMID36436177
OpenAlexW4310276444

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.